Safety of the [
tachycardia
EVENTS
Patients were closely monitored for potential AE and the need of concomitant medications; no such events were observed throughout the clinical trial. During the injection of both 10 and 50 μg mass amounts, only two patients (MTC01, MTC13) suffered from transient tachycardia and mild, short-lasting flush. Since transient tachycardia (up to 128 beats/min lasting less than 5 minutes) in the patient MTC01 was already observed before, the relation between the injection of the IMP and the AE is not clear. There was a marked increase in Ct and proCt concentrations in the blood after tracer injection in several patients with large metastatic burden of MTC. Figure Calcitonin (The laboratory test results did not change significantly during the control visits. No significant changes in the ECG recordings were observed. The performance status assessed according to Karnofsky index did not change.